Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
SUIT-AMI
1 other identifier
interventional
200
1 country
1
Brief Summary
Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2010
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedFirst Submitted
Initial submission to the registry
August 11, 2010
CompletedFirst Posted
Study publicly available on registry
August 13, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2012
CompletedAugust 13, 2010
June 1, 2010
2 years
August 11, 2010
August 12, 2010
Conditions
Outcome Measures
Primary Outcomes (3)
Major adverse cardiovascular events
Infarct size, reinfarction, motality, et.al.
1 month after PCI
Major adverse cardiovascular events
Infarct size, reinfarction, motality, et.al.
3 months after PCI
Major Adverse Cardiovascular Events
Infarct size, reinfarction, motality, et.al.
6 months after PCI
Secondary Outcomes (1)
number of participants with bleeding events
1 month
Study Arms (2)
intra-guide-catheter infusion of tirofiban
ACTIVE COMPARATORintra-thrombus-aspiration-catheter infusion of tirofiban
EXPERIMENTALInterventions
a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
Eligibility Criteria
You may qualify if:
- STEMI patients
- chest pain for less than 12hr
- plan to PCI
You may not qualify if:
- LM lesion
- stent thrombosis
- cardiac shock
- thrombocytopenia
- allergy to asprin
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
the 28th division, Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100029, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 11, 2010
First Posted
August 13, 2010
Study Start
April 1, 2010
Primary Completion
April 1, 2012
Study Completion
October 1, 2012
Last Updated
August 13, 2010
Record last verified: 2010-06